<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957931</url>
  </required_header>
  <id_info>
    <org_study_id>MSC01</org_study_id>
    <nct_id>NCT00957931</nct_id>
  </id_info>
  <brief_title>Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs</brief_title>
  <official_title>Pilot Study MUD HCT:Pts High Risk Sickle Cell,Other Non-Malignant RBC Disorders- Reduced Intensity Preparative Regimen, HAPLO-Identical Mesenchymal Stromal Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this project is to cure patients with high risk Sickle cell disease and
      other red cell disorders including thalassemia and diamond-blackfan anemia by bone marrow
      transplantation. The patients enrolled in this study will be those who lack matched sibling
      donors and therefore have no other option but to undergo bone marrow transplantation using
      matched but unrelated bone marrow or umbilical cord blood from the national marrow donor
      program registry. Since bone marrow transplantation for these disorders using matched
      unrelated donors has two major problems i.e. engraftment, or , the process of new marrow
      being accepted and allowed to grow in the the patient; and graft-versus-host disease, or the
      process where the new marrow &quot;rejects&quot; the host or the patient, this study has been devised
      with methods to overcome these two problems and thus make transplantation from unrelated
      donors both successful in terms of engraftment and safe in terms of side effects, both acute
      and long term.

      In order to accomplish these two goals, two important things will be done. Firstly, patients
      will get three medicines which are considered reduced intensity because they are not known to
      cause the serious organ damage seen with conventional chemotherapy. These medicines, however,
      do cause intense immune suppression so these can cause increased infections. Secondly, in
      addition to transplantation of bone marrow from unrelated donors, patients will also
      transplanted with mesenchymal stromal cells derived from the bone marrow of their parents.
      Mesenchymal stromal cells are adult stem cells that are normally found in the bone marrow and
      are thought to create the right background for the blood cells to grow. They have been shown
      in many animal and human studies to improve engraftment. In addition, they have a special
      property by which they prevent and are now even considered to treat graft versus host
      disease. Therefore, by using a reduced intensity chemotherapy regimen before transplant and
      transplanting mesenchymal stromal cells, we hope to improve engraftment while at the same
      time decrease the potential for severe side effects associated with a conventional transplant
      which uses extremely high doses of chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Stable engraftment was defined as absolute neutrophil count (ANC) &gt;500 cells /ÂµL for 3 consecutive days and platelet count &gt;50,000 for one week without transfusion; subsequently stable engraftment was measured by percentage of donor cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival 6 Months Following HCT</measure>
    <time_frame>6 months</time_frame>
    <description>Overall survival is reported at the count of participants alive 6 months following HCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival 1 Year Following HCT</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival is reported at the count of participants alive 1 year following HCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Disease-free Survival 6 Months Following HCT</measure>
    <time_frame>6 months</time_frame>
    <description>Disease-free survival is defined as alive without underlying disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Disease-free Survival 1 Year Following HCT</measure>
    <time_frame>1 year</time_frame>
    <description>Disease-free survival is defined as alive without underlying disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Thalassemia</condition>
  <condition>Diamond-Blackfan Anemia</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stromal cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow transplantation</intervention_name>
    <description>Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.</description>
    <arm_group_label>Mesenchymal stromal cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stromal Cells</intervention_name>
    <arm_group_label>Mesenchymal stromal cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with sickle cell disease (SCD) 1-25 years of age with an HLA-identical, but
             unrelated, donor or 1 human leukocyte antigen (HLA) allele mismatched bone marrow or
             up to 2 HLA antigen mismatched umbilical cord blood (UCB) donor with one or more of
             the following:

               -  Stroke, central nervous system (CNS) hemorrhage or a neurologic event lasting
                  longer than 24 hours.

               -  Acute chest syndrome with a history of recurrent hospitalizations or exchange
                  transfusions.

               -  Recurrent vaso-occlusive pain, 3 or more episodes per year for 3 years or more
                  years; or recurrent priapism.

               -  Impaired neuropsychological function and/or abnormal cerebral MRI scan or
                  abnormal transcranial Doppler (TCD).

               -  Stage I or II sickle lung disease.

               -  Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration
                  rate (GFR) 30-50% of the predicted normal value).

               -  Bilateral proliferative retinopathy and major visual impairment in at least one
                  eye.

               -  Osteonecrosis of multiple joints with documented destructive changes.

               -  Requirement for chronic transfusions but with RBC alloimmunization &gt;2 antibodies
                  during long term transfusion therapy.

               -  Failure of hydroxyurea (HU) therapy.

          -  Patients aged 0-21 years with transfusion dependent alpha- or beta-thalassemia who
             have an HLA-identical or 1 HLA allele mismatched bone marrow or up to 2 HLA mismatched
             UCB donor.

          -  Patients aged 0-21 years with Diamond-Blackfan anemia who have an HLA-identical or 1
             HLA allele mismatched bone marrow or up to 2 HLA mismatched UCB donor. Diamond-
             Blackfan anemia patients will only be eligible if they have failed steroid therapy.

        Exclusion Criteria:

          -  Patients with one or more of the following:

               -  Karnofsky or Lansky performance score &lt;70 (See Appendices I and II).

               -  Stage III-IV lung disease (Appendix III).

               -  GFR&lt;30% predicted normal values.

               -  Pregnant or lactating females.

               -  Active serious infection whereby patient has been on intravenous antibiotics for
                  one week prior to study entry.

               -  Any patient with AIDS or HIV seropositivity.

               -  Any patient with invasive aspergillus infection within one year of study entry.

               -  Psychologically incapable of undergoing bone marrow transplant (BMT) with
                  associated strict isolation or documented history of medical non-compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandhya Kharbanda, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kharbanda S, Smith AR, Hutchinson SK, McKenna DH, Ball JB, Lamb LS Jr, Agarwal R, Weinberg KI, Wagner JE Jr. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells. Biol Blood Marrow Transplant. 2014 Apr;20(4):581-6. doi: 10.1016/j.bbmt.2013.12.564. Epub 2013 Dec 24.</citation>
    <PMID>24370862</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <results_first_submitted>May 30, 2018</results_first_submitted>
  <results_first_submitted_qc>July 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2018</results_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sandhya Kharbanda</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mesenchymal Stromal Cells</title>
          <description>Patients received bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mesenchymal Stromal Cells</title>
          <description>Patients received bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="8" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of known transfusions prior to HSCT</title>
          <description>HSCT = hematopoietic stem cell transplantation</description>
          <units>transfusions</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.5" lower_limit="4" upper_limit="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Sickle cell disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Thalassemia major</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT)</title>
        <description>Stable engraftment was defined as absolute neutrophil count (ANC) &gt;500 cells /ÂµL for 3 consecutive days and platelet count &gt;50,000 for one week without transfusion; subsequently stable engraftment was measured by percentage of donor cells.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stromal Cells</title>
            <description>Patients received bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT)</title>
          <description>Stable engraftment was defined as absolute neutrophil count (ANC) &gt;500 cells /ÂµL for 3 consecutive days and platelet count &gt;50,000 for one week without transfusion; subsequently stable engraftment was measured by percentage of donor cells.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival 6 Months Following HCT</title>
        <description>Overall survival is reported at the count of participants alive 6 months following HCT.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stromal Cells</title>
            <description>Patients received bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival 6 Months Following HCT</title>
          <description>Overall survival is reported at the count of participants alive 6 months following HCT.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival 1 Year Following HCT</title>
        <description>Overall survival is reported at the count of participants alive 1 year following HCT.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stromal Cells</title>
            <description>Patients received bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival 1 Year Following HCT</title>
          <description>Overall survival is reported at the count of participants alive 1 year following HCT.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Disease-free Survival 6 Months Following HCT</title>
        <description>Disease-free survival is defined as alive without underlying disease.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stromal Cells</title>
            <description>Patients received bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Disease-free Survival 6 Months Following HCT</title>
          <description>Disease-free survival is defined as alive without underlying disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Disease-free Survival 1 Year Following HCT</title>
        <description>Disease-free survival is defined as alive without underlying disease.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stromal Cells</title>
            <description>Patients received bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Disease-free Survival 1 Year Following HCT</title>
          <description>Disease-free survival is defined as alive without underlying disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mesenchymal Stromal Cells</title>
          <description>Patients received bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft failure with autologous recovery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>SOS</sub_title>
                <description>SOS = Sinusoidal obstruction syndrome</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>EBV-PTLD</sub_title>
                <description>EPV = Epstein-Barr virus post-transplant lymphoproliferative disorder</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Grade II GVHD</sub_title>
                <description>GVHD = Graft-versus-host disease</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Grade III acute GVHD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenovirus reactivation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>BK virus reactivation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>CMV pneumonitis</sub_title>
                <description>CMV = Cytomegalovirus</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>CMV reactivation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>CMV viremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Disseminated toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gram-negative septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HHV-6 viremia</sub_title>
                <description>HHV-6 = Human Herpesvirus 6</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Klebsiella and enterobacter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>PRES</sub_title>
                <description>PRES = Posterior reversible encephalopathy syndrome</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sandhya Kharbanda, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <email>Sandhya.Kharbanda@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

